According to the Kidney Disease: Improving Global Outcomes 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease,11,12 GLP-1 receptor agonist treatment is suggested for individuals who are unable to use metformin or SGLT-2 inhibitors. This evidence concerns the gene SLC5A2 and chronic kidney disease.